Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BioPropolis is a commercial propolis supplement manufactured by Sigma Pharmaceutical Industries for International Business Establishment Co. (IBE Pharma). It is a natural resinous substance produced by honeybees from various plant sources, containing a complex mixture of polyphenols, flavonoids, and other bioactive compounds. In clinical research led by Mohamed Anees, BioPropolis was evaluated as an adjunctive treatment to scaling and root planing (SRP) in patients with type 2 diabetes mellitus and chronic periodontitis. Administered as a 400 mg oral capsule daily, it demonstrates antimicrobial, anti-inflammatory, immunomodulatory, and antioxidant properties. Clinical findings suggest that a 6-month regimen can significantly improve glycemic control by reducing hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels, while also decreasing serum N€-(carboxymethyl) lysine (CML) and improving periodontal clinical parameters.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BioPropolis.